摘要
目的对1株深海链霉菌Streptomyces sp. OUCT16-23的次级代谢产物进行研究,发现具有新颖化学结构和良好生物活性的化合物。方法采用V6培养基对Streptomyces sp. OUCT16-23进行发酵培养,经高效液相色谱(HPLC)纯化得到化合物1和2,并综合运用质谱(MS)、核磁共振(NMR)等波谱学方法进行结构鉴定。结果从深海链霉菌Streptomyces sp. OUCT16-23中分离得到2个放线菌素类化合物actinomycin D(1)和actinomycin V(2),并发现其对多重耐药菌Staphylococcus aureus CCARM 3090,Enterococcus faecalis CCARM 5172,Enterococcus faecium CCARM 5203和Klebsiella pneumoniae ATCC 13883具有显著的抑制活性。结论从Streptomyces sp. OUCT16-23中分离鉴定了具有优良抗多重耐药菌活性的2个放线菌素类化合物,为筛选放线菌素类抗生素高产菌株奠定了基础。
Objective To obtain secondary metabolites with novel structures and significant bioactivity from Streptomyces sp. OUCT16-23. Methods Streptomyces sp. OUCT16-23 was cultured with V6 medium, and compounds 1 and 2 were obtained with HPLC purification. The structures of compounds 1 and 2 were identified using the spectroscopic methods including MS and NMR. Results Two actinomycin-type compounds were obtained from Streptomyces sp. OUCT16-23, which were identified as actinomycin D(1) and actinomycin V(2), respectively. Compounds 1 and 2 exhibited significant inhibitory activities against multidrug resistant bacteria(MDRB): Staphylococcus aureus CCARM 3090, Enterococcus faecalis CCARM 5172, Enterococcus faecium CCARM 5203 and Klebsiella pneumoniae ATCC 13883. Conclusion Two actinomycintype compounds with significant anti-MDRB activities were isolated and identified from Streptomyces sp. ouct16-23, which laid a foundation for screening high-yield actinomycin producing strains.
作者
徐璐瑶
董玉静
鲍依蕾
金恩敬
李文利
李花月
XU Lu-yao;DONG Yu-jing;BAO Yi-lei;JIN En-jing;LI Wen-li;LI Hua-yue(Key Laboratory of Marine Drugs,Ministry of Education,School of Medicine and Pharmacy,Ocean University of China,Qingdao 266003,China;Laboratory for Marine Drugs and Bioproducts of Qingdao Pilot National Laboratory for Marine Science and Technology,Qingdao 266237,China)
出处
《中国海洋药物》
CAS
CSCD
2021年第4期40-44,共5页
Chinese Journal of Marine Drugs
基金
国家重点研发项目(2019YFC0312501)
国家自然科学基金-山东省联合海洋科学研究基金项目(U1706206)
中国科学院广东省海洋药物重点实验室联合资助开放基金项目(LMM2020-3)资助。
关键词
深海链霉菌
多重耐药
放线菌素
deep-sea Streptomyces
multi-drug resistance
actinomycin
